Search

Type 1 diabetes (T1D) polygenic risk scores (PRS) are effective tools for discriminating T1D from other diabetes types and predicting T1D risk, with applications in screening and intervention trials. A previously published T1D Genetic Risk Score 2 (GRS2) is widely adopted, but challenges in standardization and accessibility have hindered broader clinical and research utility. To address this, we introduce GRS2x, a standardized and cross-compatible method for accurate T1D PRS calculation, demonstrating genotyping and reference panel independent performance across diverse datasets. GRS2x as a unified approach facilitates accessible and portable measurement of T1D polygenic risk., Competing Interests: Conflicts of Interest ALGs spouse is employed by Genentech and holds stock options in Roche. ML, RAO and MNW have funding from Randox to study Translation of Autoimmune Genetic Scores. The University of Exeter have a licensing and royalty agreement with Randox relating to a 10 SNP T1D GRS. No other potential conflicts of interest relevant to this article were reported.